Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6.

Authors

Lorna Hopcroft¹, Eleanor M Wigmore², Stuart C Williamson¹, Susana Ros¹, Cath Eberlein¹, Jennifer I Moss¹, Jelena Urosevic¹, Larissa S Carnevalli¹, Sara Talbot¹, Lauren Bradshaw¹, Catherine Blaker¹, Sreeharsha Gunda³, Venetia Owenson⁴, Scott Hoffmann⁴, Daniel Sutton⁴, Stewart Jones⁴, Richard J A Goodwin⁴, Brandon S Willis⁵, Claire Rooney⁶, Elza DeBruin⁶, Simon T Barry⁷

Affiliations

¹ Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
² Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK.
³ Information Technology, AstraZeneca, Chennai, Tamil Nadu, India.
⁴ Imaging Sciences, AstraZeneca, Cambridge, UK.
⁵ Bioscience Early Oncology, AstraZeneca, Boston, MA, USA.
⁶ Translational Medicine, AstraZeneca, Cambridge, UK.
⁷ Bioscience Early Oncology, AstraZeneca, Cambridge, UK. [email protected].

No abstract available

Publication types

Published Erratum